3430-22-6Relevant articles and documents
Preparation method of (S)-4- (C)-3-(S)-bromopyridine (bromopyridine) (by machine translation)
-
Paragraph 0017; 0019; 0020; 0022; 0023; 0025, (2020/02/19)
The method disclosed by the invention has, the beneficial, effects :(1) that 4 - the reaction conditions are mild, the treatment is easy 4 - the method is easy to, operate, the, treatment, is easy . and the method is, easy to, operate 4 - and easy to ;(2) operate 4 - pH, 4 . (by machine translation)
Method for synthesizing 3-bromoisonicotinic acid intermediate
-
Paragraph 0009, (2019/07/04)
The invention relates to a method for synthesizing a 3-bromoisonicotinic acid intermediate, and belongs to the technical field of pharmaceutical intermediates. The process comprises the following steps: 4-methylpyridine is adopted as a raw material, and the 4-methylpyridine is reacted with bromine under the catalysis of an aluminum trichloride catalyst to form intermediate 3-bromo-4-methylpyridine; and a novel catalyst Co0.27CuO3 is added, oxygen is introduced for oxidization to form the target product 3-bromoisonicotinic acid. According to the method provided by the invention, in the oxidation reaction process, water is used as a solvent, the novel catalyst Co0.27CuO3 is introduced, the oxygen is used as an oxidant to replace a traditional KMnO4 oxidant, so that pollution of heavy metalsto the environment can be avoided; because the novel catalyst is not affected by the reaction environment, catalytic activity of the novel catalyst is not reduced, and after 25 cycles, activity of thecatalyst is not significantly reduced; and the method has the advantages of greatly improving the yield, reducing the costs, improving the safety, saving the energy, and the like, and conforms to modern chemical industry production requirements of a green reaction.
PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF
-
Page/Page column 22-23, (2014/07/08)
The present invention provides compounds of Formula III and Formula VI, and processes for their preparation. The present invention further provides use of the compounds of Formula III and Formula VI for the preparation of tofacitinib or isomers or a mixture of isomers or salts thereof.